Condition
Brain Arteriovenous Malformation
Total Trials
4
Recruiting
2
Active
2
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 2 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
3Total
Not Applicable (2)
P 1 (1)
Trial Status
Completed2
Recruiting2
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT07314047Not ApplicableRecruitingPrimary
The Liquid Embolic Agent for the Treatment of Brain Arteriovenous Malformation
NCT04572568RecruitingPrimary
Registry of Multimodality Treatment for Brain Arteriovenous Malformation in Mainland China
NCT02314377Phase 1CompletedPrimary
Bevacizumab Therapy for Brain Arteriovenous Malformation
NCT02085278Not ApplicableCompletedPrimary
Safety of Apollo Micro Catheter in Pediatric Patients
Showing all 4 trials